# Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

> **NCT02067156** · PHASE2 · COMPLETED · sponsor: **GenSpera, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** G-202

## Key facts

- **NCT ID:** NCT02067156
- **Lead sponsor:** GenSpera, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-12
- **Final completion:** 2017-02
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02067156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02067156, "Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02067156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*